May 2024 As of May 1, 2024, the Judicial Panel on Multidistrict Litigation (JPML) reports 87 cases are pending in MDL -3094 IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation
Retatrutide and LDL Cholesterol: How GLP-1 Medications Lower Heart Disease Risk Introduction The world of metabolic medicine has been revolutionized by GLP-1 receptor agonists
This study reveals that Satb2 deficiency leads to reduced production of PYY, an enteroendocrine hormone
Semaglutide has a half-life of approximately seven days, meaning roughly half of each weeks dose is still active in your system when you come in for your next injection
GLP-1 medications can support weight loss and blood sugar management, but their benefits are best realized when combined with healthy lifestyle choices
Through a comprehensive evaluation, we can determine the most suitable treatment plan for your needs